Delaware
(State
or Other Jurisdiction
of
Incorporation)
|
000-30929
(Commission
File Number)
|
13-4087132
(IRS
Employer Identification No.)
|
£ |
Written
communications pursuant to Rule 425 under the Securities
Act.
|
£ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange
Act.
|
£ |
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act.
|
£ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act.
|
Item 5.02. |
Departure
of Directors or Certain Officers; Election of Directors;
Appointment
of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
(b) |
As
a result of cost-cutting initiatives resulting from the recent clinical
failure of Sulonex (sulodexide), Keryx Biopharmaceuticals, Inc. (the
“Company”) and its Chief Accounting Officer, Mark Stier, have mutually
agreed that Mr. Stier will resign from the Company effective June
30,
2008.
|
Keryx
Biopharmaceuticals, Inc.
(Registrant)
|
||
|
|
|
Date: March 14, 2008 | By: | /s/ Beth F. Levine |
Beth F. Levine |
||
Senior Vice President, Chief Compliance Officer, General Counsel and Secretary |